Table 1.
CL-K1 IHC/RNAa | CL-L1 IHC/RNAa | MASP-1 IHC/RNAb | MASP-3 IHC/RNAb | MAp44 IHCc/RNAd | MASP-2 IHCe/RNAf | MAp19 IHCe/RNAe | MBL IHCg/RNAa | |
---|---|---|---|---|---|---|---|---|
Abortus | ++/ | +/ | ||||||
Adrenal | +++/+++ | ++/+ | −/− | |||||
Cerebellum | ++/+ | +/− | +/ | −/− | ||||
Cervix uterus | ++/+ | +/− | /+ | /+++ | /++ | /− | /− | −/− |
Colon | ++/+ | +/− | /− | /+++ | /+ | +/− | /− | −/− |
Corpus uterus | +++/ | +/ | ||||||
Esophagus | ++/+ | −/− | /++ | /+ | /− | /− | /− | −/− |
Fetal liver | +/ | ++/ | ||||||
Fetal muscle | ++/ | ++/ | ||||||
Gallbladder | +++/+++ | ++/+ | +/− | |||||
Heart | /++ | /+ | /++ | /+++ | +++/+++ | /− | /− | +/− |
Kidney | ++/++ | ++/+ | /++ | /++ | /− | ++/− | ++/++ | +/− |
Liver | ++/+++ | +++/+++ | /+++ | /+++ | +++/++ | +++/+++ | +++/+++ | +++/+++ |
Lung | ++/+ | +/+ | /++ | /+++ | /++ | +/+ | ++/− | −/− |
Muscle | +/+ | −/− | /− | /+++ | ++/+++ | /− | /− | −/− |
Pancreas | ++/++ | +/- | /− | /+++ | /− | +/− | −/− | |
Placenta | +++/++ | +/+++ | /++ | /+++ | /− | /− | /− | −/− |
Portio uterus | +/ | −/ | ||||||
Prostate | ++/+ | +/+ | /− | /+++ | /− | /− | +/− | −/− |
Salivary gland | +/+ | ++/− | −/− | |||||
Skin | ++/+ | +/− | −/− | |||||
Small intestine | ++/++ | +/+ | /++ | /+++ | /− | /++ | /− | −/− |
Spleen | ++/++ | +/− | /− | /++ | /− | /− | /− | −/− |
Stomach | ++/+ | +/− | +/ | +/− | ||||
Testis | +++/++ | +/− | /− | /++ | /− | /++ | /− | −/− |
Thymus | +/ | −/ | /− | /++ | /− | /− | /− | |
Thyroid | +++/++ | +/+ | /− | /− | /− | /− | +/+++ | −/− |
Tonsil | +/+ | −/− | −/− | |||||
Urinary bladder | ++/++ | −/+ | /− | /++ | /− | /− | /− | −/− |
IHC immunoreactivity levels were judged arbitrarily into the same categories by three independent validations (persons). Missing symbols reflect that the tissue has not been analyzed. MASP-1, MASP-3, and Map44 derive all from the MASP1 gene. MASP-2 and MAp19 derive both from the MASP2 gene.
aRelative and normalized data from HPA, GTEx, and FANTOM5 RNA expression databases (Tables S1–S3 in Supplementary Material).
bRelative and normalized data from Seyfarth et al. (30) and Degn et al. (31) (Tables S4 and S5 in Supplementary Material).
cSkjoedt et al. (32).
dRelative and normalized data from Degn et al. (31) and Skjoedt et al. (32) (Table S6 in Supplementary Material).
eDegn et al. (33) (Table S7 in Supplementary Material).
fRelative and normalized data from Seyfarth et al. (30) and Degn et al. (33) (Table S8 in Supplementary Material).
gThe Human Protein Atlas Project (antibody CAB016782).